Cellular Biomarkers of Rheumatoid Arthritis https://t.co/mLYZRX9ypm Biomarkers of RA by @jeffsparks Lots of promising biomarkers, we need validation and hopefully translation to clinical practice. @RheumNow #ACR25

• Cellular Biomarkers of Rheumatoid Arthritis

Microbiome signature for prediction of response to MTX in RA: Yay or Nay? Microbiome analysis 60pts, 23 MTX NR BL enrichment in specific species in MTX NR Looking at the graphs though, seems to be driven by a few pts Prediction model doesn't seem to perform greatly Sens 88% https://t.co/1yrSXdE6DG

• https://x.com/AurelieRheumo/status/1983534365045854650/photo/1

Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

• https://x.com/synovialjoints/status/1983534285941313978/photo/1

The next VEXAS, but also maybe we can treat it? IDH1/2 Another clonal hematopoesis known to cause heme malignancy, but also some inflamm sequelae (autoinflamm-like e.g. PMR/GCA) & you can directly inhibit it Wow. We will hear more #ACR25 LB21 @RheumNow https://t.co/WL2ai5zb8Q https://t.co/Yi31xkhLO9

• IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation - A…
• https://x.com/drdavidliew/status/1983533459428741520/photo/1

#ACR25 Abstr#LB21 Are they novel somatic variants beyond #VEXAS in driving inflammation in undiagnosed SAID?Unbiased enrichment analysis in 265 UBA1-negative adults identified IDH1/2 hotspot mutations. Cd be used to screen esp those with cytopenia. Sorry pix not allowed @RheumNow

Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 12 SC rosnilimab 100mg Q4W -2.06 400mg Q4W -2.12 600mg Q2W -2.06 PBO -1.69 >90% peripheral and synovial depletion pathogenic T cells 28 Wk Safety profile: https://t.co/XyVhJamFdp

• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1
• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1

Not all RA meds are equal for the heart. In >10K older adults w/ RA, advanced therapies lowered MACE risk (HR 0.63) vs csDMARDs, while GCs ↑ risk (HR 1.54) and undertreatment ↑ it 13-fold. Control inflammation, protect the heart. @RheumNow #ACR25 Abstract #2642

#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev

• https://x.com/Yuz6Yusof/status/1983528506056421745/photo/1
• https://x.com/Yuz6Yusof/status/1983528506056421745/photo/1

POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good but the bar is very high nowadays in PsA Questions splicing through depth of response Definitely will find a place in therapy, but where? #ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN

• https://x.com/drdavidliew/status/1983528271653564853/photo/1
• https://x.com/drdavidliew/status/1983528271653564853/photo/1

POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk 16 to 52 Pooled analysis wk 16 ACR 20 54% vs. 31% Enthesitis reduction LEI 52% vs. 45% Dactylics resolution 58% vs. 44% POETYK-PsA 1 Wk 52 ACR 20 63% ACR50 44% PASI https://t.co/LYJbU8fYwI

• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1
• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1
• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1

In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ

• https://x.com/synovialjoints/status/1983526734398881939/photo/1

Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) Choy: Depth of changes with translational data Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi) @RheumNow

Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8

• https://x.com/RichardPAConway/status/1983525475965132800/photo/1

PD-1 agonist as an induction therapy in refractory RA?? Rosnilimab ph2b: - still responding 3mo after Rx stopped - no difference between type of prior b/tsDMARD failure - safety here looks good *so far* A lot of cautious excitement in the room for this #ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N

• https://x.com/drdavidliew/status/1983525268808720677/photo/1
• https://x.com/drdavidliew/status/1983525268808720677/photo/1
• https://x.com/drdavidliew/status/1983525268808720677/photo/1
• https://x.com/drdavidliew/status/1983525268808720677/photo/1

A new approach in RA: Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety. @RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C

• https://x.com/JihaRheum/status/1983524217862951154/photo/1